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Abstract 
 
Rotavirus gastroenteritis is a leading cause of childhood mortality, killing ~1400 children 
younger than five daily, primarily through severe diarrheal dehydration. Eighty-five 
percent of this mortality occurs in developing countries where rotavirus vaccines are not 
widely implemented and are only partially effective. In those countries, it has proven 
difficult to implement the recommended supportive therapies like oral rehydration 
therapy (ORT) on a wide scale due to lack of both medical infrastructure and private 
economic investment combined with cultural bias against ORT. IgY targeting human 
rotavirus (anti-HRV IgY) shows potential as a passive immunotherapy that reduces 
rotavirus-associated morbidity and mortality, augments vaccine and ORT implementation 
measures, and, with international and local investment, overcomes the current barriers to 
rotavirus treatment and prevention. 
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Treatment and Prevention of Human Rotavirus (HRV) in Developing Countries:  
The Potential of Avian Immunoglobulin Y  
What is Rotavirus? 
Under a microscope rotavirus appears playful in its spiked symmetry of 20 faces 
and might be mistaken for a creative mathematical creature from The Phantom Tollbooth, 
an imaginative children’s novel. As innocent as it appears, this triple-layered, icosahedral 
particle is one of the leading causes of childhood death from gastroenteritis. Rotavirus 
causes the most diarrheal hospitalizations of children in the world and kills about 500,000 
children every year, or about 1440 children daily. This occurs principally in developing 
countries where current vaccines are less prominent and seem to be less effective (see 
Fig. 1) (1, 2). 
Fig. 1. Distribution of global mortality due to rotavirus in children under the age of 5 in 2008. 
Figure illustrating the distribution of mortality due to rotavirus in children younger than five-years-old. 
The darker regions represent higher mortality per 100,000 children than the lighter regions. 
 
Reprinted from J. E. Tate et al., 2008 estimate of worldwide rotavirus-associated mortality in children 
younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic 
review and meta-analysis. The Lancet. Infectious diseases 12, 136 (Feb, 2012), with permission from 
Elsevier. 
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Rotavirus’s resilient structure and severely dehydrating symptoms make it a 
powerful childhood killer. Individual rotavirus particles are incredibly stable and remain 
infectious after being outside the human digestive tract for some time (weeks to months) 
(3). Rotavirus also has a very low infectious dose of less than 100 viral particles (3). 
After establishing infection, rotavirus causes severe diarrhea and vomiting, leading to 
significant loss of bodily fluids and resulting in dehydration. If unable to rehydrate soon 
after symptom onset, the children die. Low-osmolarity oral rehydration therapy with zinc 
supplementation is currently the recommended way to prevent death from diarrheal 
dehydration (4). In the case of rotavirus, there is no therapy currently distributed that 
actually targets the infectious agent. Antibiotics are not effective against viral infection 
and no rotavirus anti-viral is available. 
Rotavirus Structure 
The rotavirus virion is composed of three layers. The innermost core contains a 
shell composed of viral protein (VP)2, which packages the double-stranded viral RNA 
genome, VP1, an RNA-dependent RNA polymerase, and VP3, a guanalyltransferase and 
methyl transferase that forms the transcription complex with VP1 (see Fig. 2) (5, 6). The 
middle layer of the particle is composed of VP6, while the outer layer is composed of a 
VP7 shell with spikes of VP4 (6, 7). The rotavirus replicates and assembles in structures 
called viroplasms that are created by the virus in the cytoplasm of the host cell, near the 
cell nucleus (8). The core and middle layers assemble in the viroplasm and then bud 
through the endoplasmic reticulum (ER), acquiring the outer layer in the process (9). It 
seems that rotavirus exits the apical portion of epithelial cells via an atypical vesicle 
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budding that bypasses the Golgi 
apparatus.  However, release may also 
be lysis mediated (9, 10). 
The rotavirus genome codes for 
a total of 12 proteins, the six structural 
proteins (VP1-VP4, and VP6-VP7) that 
create the virion and six non-structural 
proteins (NSP1-NSP6) that aid in 
various aspects of infection and 
replication inside the cell. The six non-
structural proteins have unique 
responsibilities. NSP1 seems to play a 
large part in the virulence of the virus 
by countering many innate immune 
defense mechanisms. NSP2 and NSP5 
are components of the viroplasm; NSP5 specifically recruits proteins to the viroplasm (8, 
11). NSP3 assists in shutting down host RNA translation and directs machinery to 
promote viral RNA translation (12). NSP4 acts as an enterotoxin which promotes 
secretory diarrhea and dissemination of the virus throughout the gut via various 
mechanisms still under investigation (6, 13). NSP4 also acts as the transmembrane ER 
receptor to which the double layered particle binds, initiating the budding through the ER 
to acquire the final layer of the virion. The last non-structural protein, NSP6, is the least 
Fig. 2. Illustrated cross-section of a rotavirus. 
The three layers of the rotavirus encapsulate the 11 
segments of double stranded RNA genetic material 
(dsRNA). The inner layer is composed of VP1, VP2, and 
VP3. VP6 makes up the middle layer, while VP4 and 
VP7 comprise the outer layer. As the outermost antigens, 
VP4 and VP7 are the principle neutralization antigens 
(targets for antibodies to bind and inhibit virulence). 
Thus, VP4 and VP7 are the main immunogenic 
components of the current rotavirus vaccines. 
 
Reprinted by permission from Macmillan Publishers Ltd: 
Nature reviews. Microbiology J. Angel, M. A. Franco, H. 
B. Greenberg, Rotavirus vaccines: recent developments 
and future considerations. Nature reviews. Microbiology 
5, 531 (Jul, 2007). 
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characterized, but seems to regulate the assembly of NSP5 in the viroplasm structure and 
may regulate mitochondrial function during infection (14-16). 
Currently, the VP7 shell and the VP4 spikes of the outer protein coat are known to 
induce a neutralizing antibody response from the immune system (17). These proteins are 
also used to identify the different genotypes and serotypes (strains of the same 
microorganism species with different surface antigens) of human rotavirus. VP7 is a 
glycoprotein and determines the G-type of the virus (e.g., G1, G2), while VP4 is a 
protease-activated protein and determines the P-type of the virus (17).  Because the 
rotavirus genome contains 11 segments of double stranded RNA, there is a large amount 
of genetic reassortment when more than one strain of rotavirus simultaneously infects an 
individual (18). Thus, there are many different combinations of G and P types. However, 
90% of circulating rotavirus is comprised of five strains: G4P4, G1P8, G3P8, G4P8, 
G9P8 (17). 
Epidemiology of Infection 
Human rotavirus is transmitted principally via a fecal oral route and seems to be 
only transmitted through humans. The principal reservoirs of infection are the human 
gastrointestinal tract and stool of infected individuals (3). Approximately 2 days before 
the start of diarrhea, the individual begins shedding significant amounts of virus in stool. 
That shedding continues for up to 10 days after the onset of symptoms in healthy 
individuals and longer (up to 30 days) in persons with compromised immune systems (3). 
In developing countries, most rotavirus infections (75%) occur prior to the age of one 
(17). 
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The Need for Prevention and Therapy 
Since rotavirus is highly infectious and quite resilient, it is practically impossible 
to prevent exposure and infection solely through sanitation. The high incidence of 
rotavirus infection is astonishing and essentially all children are infected by rotavirus by 
the age of five in both developing and industrialized countries (17). This global, cross-
cultural incidence of infection indicates that simply increasing hygienic practices in 
developing countries will not prevent children from becoming infected with rotavirus. 
Rather, a method of decreasing the severity of infection and assisting the body in fighting 
the disease seems to be the best way to combat this childhood killer. 
The Theory Behind Vaccination 
The concept of vaccination is based on the natural development of immunity 
where initial exposure to a pathogen allows a faster, more efficient immune response 
upon secondary exposure to the same pathogen. A vaccine mimics the initial infection, 
priming the body with a weakened form of a pathogen so that the body is prepared to 
defend itself against subsequent infection with the fully virulent pathogen. 
Studies in Mexico (1996) and Guinea-Bissau, West Africa (2002) initially 
indicated that the first infection with rotavirus is the most severe followed by 
significantly reduced severity of subsequent infections (19). The first infection was found 
to be about 70% effective in preventing additional instances of rotavirus diarrhea. These 
findings support the hypothesized value of a rotavirus vaccine. Thus, scientists have 
worked to formulate vaccines with live, attenuated rotavirus that is capable of causing a 
mild, natural infection and inducing the associated immune response from the host. Then, 
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when the child is infected by the stronger, wild-type rotavirus, the body is prepared to 
respond to the infection and prevent severe gastroenteritis.  
RotaShield 
In 1998, a rotavirus vaccine using a rhesus (monkey) human reassortant strain of 
rotavirus (known as RotaShield) was licensed in the United States after demonstrating 
82-91% efficacy against severe gastroenteritis caused by rotavirus (17). Reassortant 
strains arise when two different strains of a virus infect the same cell and the genetic 
material from both strains recombines in different ways to produce a new strain with a 
mixture of the genetic material from the two parental strains. This reassortment can be 
induced in a laboratory to create viral strains that are less infectious but contain the key 
human rotavirus epitopes and induce a protective immune response. RotaShield was a 
tetravalent vaccine and contained four reassortant strains presenting the most common G 
types, G1-4 (20). G1, G2 and G4 were human rotavirus serotypes substituted into rhesus 
virions, while G3 was expressed only as a rhesus rotavirus serotype (21). However, 
RotaShield was quickly withdrawn from the market after a clear association with 
intussusception (where one portion of the intestine folds into another portion, a sort of 
telescoping of the intestine) was discovered during its first year of licensure (17). Experts 
determined that the rate of association was approximately 1 occurrence per every 10,000 
vaccinated children (20). 
RV5 and RV1 
Fortunately, two other vaccines, RV5 (known as RotaTeq®) and RV1 (known as 
Rotarix®) were licensed in the US in 2006 and 2008, respectively, after undergoing 
extensive clinical trials (22). RV5 is a pentavalent vaccine containing five bovine-human 
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reassortant strains of rotavirus expressing human G1-4 as well as P1A[8]; the 
immunogenic importance of VP4 (which determines the P type of the virus) was realized 
after the development of RotaShield and human VP4 was not included in the first vaccine 
(20). RV5 is distributed in 2mL vials with the viruses suspended in a buffer solution (3). 
Each vial contains approximately 2x106 infectious units (IUs) of each of the five strains 
of rotavirus. The United States Advisory Committee on Immunization Practices (ACIP) 
recommendations for administration advise a series of three oral doses starting at 2 
months old and repeated at 3 and 4 months with a minimum of 4 weeks between doses 
(23). They recommend that the maximum age for the first dose of RV5 is 14 weeks and 6 
days, and the maximum age to complete the series is 8 months.  
In 2008, the monovalent RV1 vaccine was also licensed for use in the US (22). A 
naturally attenuated (rather than laboratory attenuated or weakened) human strain of 
rotavirus, the P1A[8]G1 strain, contained in RV1 includes the most common human 
serotypes of VP7 and VP4 (20). RV1 is distributed as a freeze-dried powder which is 
reconstituted in a liquid immediately before oral administration in 1mL doses (3). Each 
dose contains 106 IUs of the one rotavirus strain. According to the ACIP, RV1 should be 
administered in a series of two doses, 4 weeks apart (23). The appropriate age range for 
administration of RV1 and RV5 is the same according to the ACIP, but the label 
recommendations for administration from the vaccine developers vary slightly (3). 
116E 
From 2011 to 2012, clinical trials were performed using a new monovalent 
human-bovine natural reassortant strain of rotavirus, named 116E, as a vaccine (21, 24, 
25). This G9P[11] strain is a unique, naturally attenuated reassortant strain that was 
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discovered and isolated as a vaccine candidate because it induced asymptomatic rotavirus 
infection in neonates in India (25). The 116E vaccine contains the bovine P gene and 10 
other human genes (24). It is administered in three doses at about 6, 10, and 14 weeks of 
age. Each dose is administered 5-10 minutes after the administration of 2.5ml of a citrate 
bicarbonate buffer to raise the pH of the harsh gastric environment (24). 
Vaccine Efficacy 
In various high- and middle-income locations in Latin America, Europe, and Asia, 
clinical trials found RV1 to be highly effective (85%-96%) against severe rotavirus 
gastroenteritis through the second year of life (17). RV5 was found to have 98% efficacy 
against severe rotavirus gastroenteritis and 74% efficacy against any severity of rotavirus 
gastroenteritis caused by serotypes G1-4 in the United States and Finland (17).  Over the 
long-term, both RV5 and RV1 have proven highly effective in preventing rotavirus 
gastroenteritis caused by all strains of human rotavirus in the United States (since 2006 
and 2008 respectively) and in other developed countries (17, 26).  
In middle-low and low-income countries, however, clinical trials of RV1 and 
RV5 demonstrated much lower efficacy rates and were found to be only 51%-64% 
effective against severe rotavirus gastroenteritis. The reasons for this are under 
investigation. The middle-low and low-income countries evaluated included the African 
nations of South Africa, Malawi, Kenya, Ghana, and Mali, and the Asian countries of 
Vietnam and Bangladesh (17). Further, trials utilizing RV5 demonstrated substantially 
reduced protection in the second year of life (19). For maximal impact, rotavirus vaccines 
need to be effective through the second year of a child’s life (17). 
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For 116E, the vaccine exhibited an efficacy of 56% against severe rotavirus 
gastroenteritis in the first year of life, while the efficacy in the second year of life was 
found to be about 49% (27). The vaccine was also not linked to a significantly increased 
risk of intussusception. While this is promising, the clinical trials were not performed on 
a large enough sample size to detect low-risk associations of vaccination to 
intussusception or other adverse side effects. Thus, to ensure safety, further evaluation 
and surveillance are warranted as the vaccine is implemented. (28). 
In 2009, in response to the results of clinical trials of RV1 and RV5, the World 
Health Organization (WHO) recommended global integration of RV1 and RV5 into 
immunization programs (22). Regardless of their varying levels of efficacy, it remains 
clear that implementation of rotavirus vaccination on a global scale would significantly 
reduce the childhood death due to this disease, likely saving the lives of about 200,000 
children annually.  
Impediments to vaccine implementation 
Even though the WHO recommended global incorporation of rotavirus vaccines 
into immunization programs in 2009, as of November of 2015, only five of the 15 
countries with the highest mortality were using the rotavirus vaccine(s) (29). In order to 
preserve life, it is important to understand the impediments to vaccine implementation 
faced by developing countries. First, there is a significant cost issue (30). In order for 
manufacturers to produce the rotavirus vaccines, they performed extensive research and 
development. Further, due to the intussusception associated with RotaShield, RV5 and 
RV1 underwent extremely extensive clinical trials to prove their safety and efficacy. This 
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means that the newer rotavirus vaccines must be sold at a higher price to ensure adequate 
profit while the manufacturers control the market. 
When RV5 and RV1 reached the market, they were 132 and 90 times more 
expensive than the most inexpensive vaccine included in the Expanded Program on 
Immunization (EPI) facilitated by the WHO (30). Fortunately, in 2011, both 
manufacturers offered to provide their vaccines at reduced price to the countries eligible 
for the Global Alliance for Vaccines and Immunizations (GAVI) funding. For those 
countries, manufacturers are offering RV1 at US $2.50 per dose and RV5 and US $3.50 
per dose (30). However, even at these reduced prices, rotavirus vaccines are still one of 
the most expensive vaccines in the EPI. Compounding the issue are implementation 
costs, including the cost of training for effective vaccine administration, crucial cold 
storage, surveillance, etc. (29, 30). Thus, cost is a significant impediment to 
implementation in developing countries with limited financial resources and 
infrastructure. 
The company in India manufacturing the new 116E vaccine has committed to 
make its doses available at a price of $1 per dose which is far more affordable than the 
other vaccines provided to GAVI countries (28). However, GAVI countries receiving 
international funding for vaccines only co-finance 40 cents per full vaccine series (two or 
three doses) of RV1 or RV5 through the program—a supplemented price that is 
significantly lower than the full 116E pricing (28).  This presents two issues: first, it is 
not clear that many countries would be able to afford the 116E vaccine without additional 
funding assistance. Further, if GAVI countries choose the RV1 or RV5 vaccine while 
they can qualify for GAVI funding, it is unclear if they will have the ability or initiative 
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to continue providing rotavirus vaccination once they are responsible for paying for the 
vaccines without GAVI assistance (29). 
Impediments to vaccine efficacy in developing countries 
In addition to the practical/financial challenges to global vaccine implementation, 
recent research in developing countries indicates that there may be significant 
physiological impediments to vaccine efficacy in these locations. One inhibition to 
rotavirus vaccine efficacy could be trans-placental anti-HRV IgG. A trial performed in 
2013 showed that high levels of maternal IgG crossing the placenta to the child led to 
diminished immune response when the children were given a live oral rotavirus vaccine 
(116E) (31). However, this trial also found that the diminished immune response could be 
overcome by increased vaccine dosage.  
Studies in 2010, 2011, and 2013 involving breastfeeding women across multiple 
countries all found that women in developing countries had the highest titers of 
antibodies capable of neutralizing rotavirus vaccines strains (32-34). The 2013 study also 
indicated that other elements of maternal breast milk may play a role in decreasing the 
vaccine’s ability to induce an immune response in the infant. However, another study 
where mothers were encouraged to withhold breastfeeding for thirty minutes prior to and 
after vaccine administration found no additional vaccine efficacy when breastfeeding was 
withheld (35). The withholding period was short, so the significance of these findings is 
not entirely clear. 
There is also mixed evidence regarding the interference of live oral polio vaccines 
(OPV) with rotavirus vaccine efficacy. The rotavirus vaccine does not harm the 
immunogenicity of OPV, but studies do indicate that concurrent administration of OPV 
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and the oral rotavirus vaccine interferes with rotavirus vaccine immunogenicity at least 
for the first dose. However, this lowered immune response seems to be overcome by 
subsequent doses of the vaccine series. While immunogenicity seems to be about the 
same at the end of a full dosage of RV1 or RV5 administered with or without the live oral 
polio vaccine, the actual protective efficacy may not be the same in developing countries. 
It is unclear if vaccine immunogenicity directly correlates with protective efficacy in 
those countries, so experts believe this question warrants further investigation (36). 
A study in India published in 2011 found that even natural rotavirus infection did 
not lessen the intensity of rotavirus-induced diarrhea until a child was infected two or 
three times (37). For the most common strain of rotavirus, G1P[8], even reinfection with 
the same strain (homotypic infection) was not any less severe than heterotypic infection. 
The protection of three natural infections against symptomatic rotavirus infection finally 
reached about 80% against moderate or severe diarrhea. Since vaccination is based on the 
observation that a host responds more efficiently to a pathogen after the first infection, 
this finding raises questions in the context of certain countries about the validity of the 
ideological basis for the efficacy of vaccination against rotavirus. The reasons for this 
reduced natural protection are unclear, but reduced protection could be due to a 
significantly higher viral titer and earlier age of infection in developing countries (19).  
A further problem for vaccination arises when immune systems are compromised. 
In patients with severe combined immunodeficiency (SCID) for example, the live 
rotavirus vaccine can cause actual rotavirus infection (38).  
Ultimately, the limited efficacy of presently licensed (and in process) rotavirus 
vaccines in developing countries means that even with 100% implementation, hundreds 
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of thousands of children would likely still die annually from rotavirus. Clinical trials 
demonstrated an efficacy of 48% for pentavalent vaccine in developing countries in Asia 
(Vietnam, Bangladesh) and an efficacy of 39.3% in developing countries in sub-Saharan 
Africa (39, 40). As mentioned earlier, the efficacy of the new 116E was similar, 
demonstrating about 50% efficacy in India where its clinical trials were performed (24). 
In addition to limited efficacy once administered, three compounding factors make it 
difficult to realize full vaccination benefits. First, according to the recommended regime, 
vaccine sequences must be completed in the first three to eight months of a child’s life 
(depending on the vaccine used), thus a child must be brought on a regular basis, early on 
in life, to a place where the two or three dose vaccines are administered. Second, there 
will always be a subset of the population that is immune compromised and thus incapable 
of using the live vaccines and potentially hurt by them. Lastly, for the full public health 
potential of a vaccine to be realized it would need to actually prevent rotavirus infection 
not simply prevent the severe gastroenteritis (22). Avoiding severe symptoms is 
beneficial, but infection, viral proliferation, and viral shedding still occur, allowing the 
spread of rotavirus. Thus, unless infection is completely prevented, human rotavirus will 
continue to infect and possibly kill those who cannot be or are not protected by 
vaccination. 
Treating Rotavirus: The Current Recommended Approach 
Currently, rotavirus is treated symptomatically; there is no treatment targeting the 
actual infection. Current treatments target symptoms of gastroenteritis, principally 
dehydration which serves as the primary mechanism of mortality caused by rotavirus 
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infection. Oral rehydration solution combined with zinc supplementation is the most 
effective combination known to date able to treat/prevent dehydration due to diarrhea (4). 
Oral Rehydration Solution 
Oral rehydration solution (ORS) is composed of glucose and electrolytes that help 
the body absorb water through the digestive tract. In 2004, the WHO and the United 
Nations Children’s Emergency Fund (UNICEF) issued a joint statement on the treatment 
of acute diarrhea, noting that a reduced-osmolarity rehydration solution (with less glucose 
and salt) was more effective than the original ORS in promoting hydration and reducing 
diarrhea and vomiting (41). The lower osmolarity formulation aids the absorption of 
water into the body by reducing the concentration of the solutes. According to WHO and 
UNICEF recommendations, the reduced osmolarity ORS is composed of sodium chloride 
(2.6 g/L), glucose, anhydrous (13.5 g/L), potassium chloride (1.5 g/L), trisodium citrate, 
dihydrate (2.9 g/L) (41). 
Zinc Supplementation 
Zinc supplementation has been very beneficial to the treatment and prevention of 
diarrhea in children in developing countries (42-44). In most cases, 20mg of zinc 
supplement per day (10mg for children under 10 months) for 10-14 days reduces the 
frequency and duration of diarrhea and reduces the incidence of diarrhea for about two to 
three months following the supplementation period (41). However, there are conflicting 
results from studies specific to rotavirus, with some finding that zinc supplementation 
was not efficacious in children with rotavirus infection/co-infection while other studies in 
China indicate that zinc supplementation is beneficial to treat rotavirus-induced diarrhea 
(44, 45). There does seem to be a role for zinc ions in rotavirus protein stability, so this 
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may be one reason why zinc supplementation may not be as effective in reducing 
rotavirus-induced diarrhea (46). 
Intravenous Rehydration 
In cases of severe diarrheal dehydration (SDD), the WHO manual on the 
treatment of diarrhea recommends slightly different guidelines for addressing 
dehydration. Instead of oral rehydration therapy, WHO recommends rapid intravenous 
rehydration administered in a hospital (47). The recommended treatment plan suggests 
administering 30ml/kg in the first hour (for infants under 12 months) or 30 minutes (for 
older children) followed by administration of 70ml/kg in 5 hours (or 2.5 hours for 
children older than 12 months). However, in SDD a variety of other complicating factors 
affect the efficacy of treatment (48). In particular, many children with SDD suffer from 
hypokalemia (low levels of potassium in the blood stream) and/or hypernatremia (high 
levels of sodium) (48). Both of these situations are common and neither is well addressed 
by the typical intravenous solution such as Ringer’s lactate solution, which actually 
contains high sodium and low potassium concentrations (47, 48). WHO recommends 
administering some ORS even while the child is severely dehydrated to try to balance 
these electrolytes (47). Studies also indicate that ORS is more effective than intravenous 
solutions alone for stabilizing electrolyte imbalances (49). Thus, it is clear that the sooner 
the child can receive ORS the better. Unfortunately, in under-resourced settings, IV 
therapy may not even be available. With this in mind, the importance of stabilizing the 
child so that he or she is able to retain ORS without nasogastric administration is clear 
and is therefore a key goal of any rotavirus treatment regime applicable to the highest 
burden areas.  
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Impediments to Implementation and Efficacy 
A 15-year UN initiative started in 2000, the Millennium Development Goals, had 
as its fourth goal (MDG4) the reduction of under-five mortality by two-thirds from what 
it was in 1990 (50). While almost able to achieve MDG4 with an approximately 50% 
reduction, in 2015 about 5.9 million children under the age of 5 still died. Diarrhea alone 
accounted for 9% of these deaths (29, 50). Of specific interest is the fact that the 
proportion of severe diarrhea (and likely death) due to rotavirus relative to the total of 
severe, hospitalizing diarrhea has at least doubled over the past 15-20 years (1). In 2013, 
recognizing that the 2015 MDG4 was far from being reached for many of the poorest 
countries, UNICEF and WHO set forth a Global Action Plan for the Prevention and 
Control of Pneumonia and Diarrhoea (GAPPD). The GAPPD set forth a goal of 90% 
coverage with ORS and zinc treatment for diarrhea of 15 target countries with the highest 
mortality due to pneumonia and diarrhea, the two leading childhood killers, by 2025. 
Additionally, the GAPPD also established the Sustainable Development Goal 3.2 of 
ending preventable deaths of infants and children by the year 2030 (51).  
As anticipated, by the end of 2015, ORS and zinc coverage was still depressingly 
low. Only two of the countries had achieved an ORS coverage of over 50% for children 
with diarrhea and none of the countries had coverage over 11% with zinc supplements 
(29). While implementation of coverage of both pneumonia and diarrhea interventions 
was much lower than hoped, countries consistently had more difficulty implementing 
diarrhea interventions. Over all, in the countries experiencing the highest morbidity and 
mortality due to rotavirus, only about 34% of children with diarrhea receive any type of 
ORS (original or low-osmolarity) and less than 5% receive any sort of zinc 
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supplementation (4). Further, international attention has shifted to other diseases like HIV 
and malaria which kill fewer children under the age of 5 than “simple” diarrhea and 
pneumonia but have more of a dramatic treatment appeal. 
Practical impediments. Bangladesh is one country that has successfully scaled 
up its ORS and zinc coverage of diarrhea. Unger et al. identified a strong private-sector 
pharmaceutical industry and in-country production as being key to its success in 
developing and implementing ORS and zinc treatments (4). In the 2015 assessment of 
progress towards GAPPD goals, the International Vaccine Access Center identified three 
success factors in countries that had sustained greater than 50% coverage of ORS for 
three years. These factors included (i) both public and private sector engagement and 
stakeholders, (ii) integrated efforts to increase demand in both the public and private 
sector, and (iii) other support factors including political stability and designated funding 
(29). It seems difficult for countries lacking these factors to successfully implement 
treatment. 
Overall, the most recent assessments have concluded that each country faces 
unique challenges to diarrheal therapy implementation (4, 29, 50). Thus, each country 
needs to develop an individualized action plan, identifying relevant economic and 
cultural barriers to therapy implementation which will likely need to be addressed by the 
combined efforts of the public and private sector. 
Cultural impediments. While each nation has its unique barriers to ORS and 
zinc implementation, one overarching difficulty in ORS implementation is the perception 
that it is not a “medicine” (4). ORS does not quickly reduce diarrhea and allows rotavirus 
to run its course but prevents death from dehydration. Thus, many caregivers demand 
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antibiotics or antidiarrheal medications which harm the patients more than help them. 
Further, the lack of access to hospitals in rural areas is a problem. When the diarrhea and 
vomiting become too severe for normal ORS administration, these communities are 
unable to access a hospital with the resources for nasogastric or IV administration of 
rehydration fluids necessary to save lives. 
The Need for Another Therapy 
In light of the current difficulties facing vaccine success and ORS 
implementation, “[t]he need for an approach to complement but not compete with 
prevention by immunization and treatment with ORS, therefore, is certain,” Dr. George 
Fuchs, professor of pediatrics practicing in Pediatric Gastroenterology and Nutrition at 
the University of Kentucky, stated in an invited commentary on an adjuvant rotavirus 
therapy (52). 
In 2013, when the WHO published its action plan to address pneumonia and 
diarrhea, a recurring theme emerged throughout its evaluation of previous successes and 
failures (51). Moving forward, the GAPPD emphasized the necessity of involvement of 
local communities and industry in the treatment/prevention of diarrhea alongside the 
support of the larger international organizations through collaborative efforts. To this 
end, the GAPPD states: 
The GAPPD is committed to the promotion of research, including community-
based action research and sociocultural research on knowledge, attitudes, 
perceptions, cultural practices and health seeking behaviours.…, there will be a 
need for research on delivery strategies, on overcoming barriers to interventions 
and on better ways for implementation.…. Research efforts to control pneumonia 
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and diarrhoea in children must include building research capacity in the countries 
most affected. (pg. 34 (51)) 
Keeping in mind the need for an adjunct therapy, sensitivity to cultural attitudes and 
practices, and investigation augmenting local research needs and abilities, avian 
immunoglobulin Y (IgY) seems quite promising as a passive oral immunotherapy for 
rotavirus in developing countries. 
Research on using IgY to treat intestinal diseases has been performed across the 
world for approximately thirty years. In particular, anti-HRV IgY has been a subject of 
research in Myanmar, India, China, Argentina, Japan and Bangladesh within the past 15 
years (53-56). As knowledge of avian biology, immunization adjuvant systems, and IgY 
administration systems increased over the past decade, IgY technology has emerged as an 
affordable, sustainable, and effective means of producing specific antibodies. In 
particular, since much research on efficient production and extraction of antibodies from 
chickens is available to the public, IgY technology can be developed in any country by 
any business that wishes to do so. Thus, it is worth understanding the potential of IgY to 
address current gaps in the treatment/prevention of diarrheal death as a unique therapy 
that lends itself to both international investment and collaboration with local research 
facilities. 
What is IgY? 
 Immunoglobulin Y is an antibody found in chicken egg yolks. By vaccinating 
chickens with a microorganism or other antigenic substance, IgY that specifically binds 
that microorganism is produced by the chicken and then transferred into the egg yolk. 
IgY is simpler and cheaper to produce than many other mammalian antibodies (which 
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require bleeding and careful purification from other reactive serum components) and can 
be used for various diagnostic assays and laboratory procedures. Since chicken eggs are a 
natural part of the human diet, IgY works well as a component of passive oral 
immunotherapy for various enteric diseases such as rotavirus. Since production and 
extraction is relatively easy and inexpensive and IgY is easy to store while retaining 
antigen affinity, IgY shows promise for development and implementation in developing 
countries where extensive lab equipment, special storage systems and refrigeration are 
limited. 
Avian Immunity 
As a part of their immune system, adult 
chickens have three immunoglobulin (antibody) 
classes: IgA, IgM, and IgY (57).  In mammals, a 
developing embryo is protected via placental transfer 
of IgG and, once the young is born, further immune 
protection is conveyed through mucosal antibodies 
secreted in the breast milk (57). However, for birds, 
all immune protection must be conveyed to the chick 
in the egg. IgM and IgA are transferred to the chick 
in the egg white, while IgY is selectively transferred 
to the egg yolk from the blood serum in a receptor 
mediated process (see Fig. 3) (57, 58). As the only 
antibody class found in the egg yolk, IgY is easy 
Fig. 3. Antibodies present in the avian 
egg. Antibodies are transferred from the 
hen blood serum into the developing 
egg. IgY is selectively transported to the 
egg yolk while IgA and IgM remain in 
the egg white.  
 
Figure reproduced from J. Kovacs-
Nolan, Y. Mine, Egg yolk antibodies for 
passive immunity. Annual review of food 
science and technology 3, 164 (2012). 
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isolated from the other immunoglobulins. On average, a 50-gram egg can contain 
between 100-150mg of IgY (57).  
Antigen Specific IgY 
While different breeds of laying hens may have different typical amounts of IgY, 
once the chickens are immunized, they all seem to contain similar amounts of IgY in the 
egg yolks (59). In order to produce IgY that binds specific antigens, the chicken must be 
immunized with that antigen. This is typically done intramuscularly with an initial dose 
of antigen, followed by a sequence of booster shots. Depending on the type of adjuvant (a 
substance encouraging an immune response) used, varying numbers of booster shots are 
needed to maintain high-levels of antibody production (60). Once the antibodies are 
produced in the chicken serum, they are transferred to the eggs rapidly with substantial 
quantities of antigen specific IgY present in the yolk about a month after initial 
inoculation (53). With appropriate booster immunizations, high titers of IgY can be 
maintained for over a year. Interestingly, older laying hens who have completed two 
laying cycles (considered to be “spent” for commercial production of eggs for 
consumption) still produce eggs with high titers of antigen specific IgY and therefore 
may be a particularly cost-effective source of IgY (57, 61).  
In the case of rotavirus, research demonstrates that immunization with whole 
rotavirus particles initiates a polyclonal antibody response which provides more effective 
neutralization than immunization with one viral particle (e.g., VP6) (56). Successful 
clinical trials in 2012 utilized a “Rotamix IgY” which was produced by combining two 
clinical strains of rotavirus in vaccination, stimulating production of IgY against various 
epitopes of both strains. The Rotamix IgY was able to cross react with all major clinical 
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strains of rotavirus in neutralization assays demonstrating its ability to provide passive 
immunity against human rotavirus (54). Unlike vaccination (active immunity), passive 
immunotherapy does not require a strong host immune system. The antibodies from the 
donating organism (in this case a chicken) neutralize the infectious agent in the recipient 
host (see Fig. 4). 
 In the past decade, various adjuvant systems have been tested to determine the 
most efficient way of stimulating a thorough avian immune response to the vaccination. 
Typically, incomplete Freund’s adjuvant (IFA) is used with vaccinations in order to 
promote an immune response but not damage the tissue of the animal. A 2007 study 
showed that C-phosphate-guanosine-oligodeoxynucleotide (CpG-ODN) supplementation 
Fig. 4. The difference between active and passive immunity. 
(a) Active immunity, induced by rotavirus vaccination of humans, requires a host immune response to 
fight the pathogen. (b) Passive immunity, provided by avian IgY, does not require a host immune 
response to neutralize the pathogen. This is particularly beneficial when the host immune system is 
weakened or not well-developed. 
 
Figure reproduced from J. Kovacs-Nolan, Y. Mine, Egg yolk antibodies for passive immunity. 
Annual review of food science and technology 3, 165 (2012). 
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of IFA was cost-effective and increased the yield of antigen-specific IgY (compared to 
IFA alone) by an average of 430% in each egg with a maximum increase of 942% (60). 
CpG-ODN mimics a common component of bacterial membranes and induces a strong 
immune response. In milligrams, this increase in IgY yield equates to 96mg of antigen 
specific IgY per egg (60). With a conservative estimate of 5 eggs per week, one laying 
hen could produce about 25,000mg of antigen specific IgY in one year. Since most laying 
hens produce an average of 325 eggs per year, one hen could produce closer to 30,000mg 
of specific IgY annually (60, 62). In the 2012 clinical trial, pediatric patients were treated 
successfully with about 30mg of HRV-specific IgY daily as an adjunct to standard 
supportive therapy (dosage clarified through personal correspondence with Dr. Shofiqur 
Rahman, February 8, 2016) (54). Even with a higher estimate of 100mg of antigen 
specific IgY administered daily, one laying hen could hypothetically produce 250 daily 
quantities of pediatric rotavirus treatment annually. 
Isolation of IgY 
After separation of the yolk from the egg white, IgY must be extracted from the 
rest of the yolk lipid and protein components. There are a variety of safe, cost-effective 
methods that can be used to extract IgY from the rest of the yolk contents using solvents 
such as polyethylene glycol (PEG) and salts such as ammonium sulfate to precipitate IgY 
(see Appendix A) (62-64). In a particularly simple method, high-purity, high-yield, high-
activity IgY (98.7% pure, at 80.9% yield, with 96.3% activity) was separated from the 
yolk using a sequential method without the use of toxic compounds or organic solvents 
(see Fig. 5) (64). In this same protocol, another protein in the egg yolk, phosvitin, which 
demonstrates antibacterial properties, is extracted from the pellet parallel to IgY 
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extraction from the supernatant (the liquid portion of the yolk sample following 
centrifugation) by a similar sequential method. 
Storage of IgY 
There are a variety of ways that eggs can be stored and retain active IgY in their 
yolks. Eggs can be refrigerated at 4°C for at least 6 months, stored at typical commercial 
refrigeration temperatures (10-12°C) for at least two weeks (this was the only period 
tested), or stored at room temperature for at least one month (60, 65). Once isolated, IgY 
Fig. 5. Schematic diagram of the sequential separation of IgY and phosvitin from egg yolk. 
An outline of the simple, sequential process of isolating both IgY and phosvitin from the 
chicken egg yolk. This method result in an IgY product that is 98.7% pure, at 80.9% yield, with 
96.3% activity. 
 
H. Y. Lee, E. D. N. S. Abeyrathne, I. Choi, J. W. Suh, D. U. Ahn, Sequential separation of 
immunoglobulin Y and phosvitin from chicken egg yolk without using organic solvents. Poultry 
Science 93, 2675 (October 1, 2014).  Reproduced by permission of the Oxford University Press. 
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can be stored in a variety of ways; for example, it can be suspended in phosphate-
buffered saline (PBS) and frozen while retaining activity for at least a year (62). If IgY is 
freeze-dried with low levels of sugars, studies indicated that the powder is stable at room 
temperature for a year or more retaining almost all of its activity (66). If freeze dried 
without a sugar, IgY is stable for at least three months and retains most of its activity. 
IgY retains its activity at temperatures up to 70°C, high pressures (up to 4,000 kg per 
cm2) and can be stabilized further against temperature and pressure using various sugars 
as mentioned above (67). 
Unique Characteristics of IgY 
 Like all antibodies, IgY has an antigen binding region (Fab) and a constant (Fc) 
region which binds Fc receptors on cells activating the appropriate immune response 
(inflammation, chemotaxis, fever, etc.). While IgY is similar in function to the 
mammalian IgG, the 
Fc region of the 
antibody is unique 
thus allowing it to 
bind antigen without 
inducing an 
additional response 
via the complement 
system, or bacterial or 
mammalian Fc 
receptors (see Fig. 6) 
Fig. 6. Comparison of IgY and IgG. 
Both avian IgY and human IgG contain the usual Fab  (antigen binding) and Fc 
(constant) regions, the differences between the two are significant enough that 
avian IgY does not activate the mammalian immune response to IgG. 
 
Figure reproduced from: S. Muller, A. Schubert, J. Zajac, T. Dyck, C. 
Oelkrug, IgY antibodies in human nutrition for disease prevention. Nutrition 
journal 14, 109 (2015). 
TREATMENT OF HRV  29 
(58, 67-69). It also does not usually permeate the gut barrier or enter the blood stream. 
However, in a neonatal piglet model using a crude extract of IgY, some anti-IgY IgG was 
found in the piglet serum (56). Assessing the presence of anti-IgY IgE (IgE is the 
antibody involved in allergic reactions) is an important next step in research to ensure 
that an allergic reaction will not be promoted by a particular extract of IgY (56). 
However, because of the unique nature of IgY, it can be used to neutralize various 
microbes that infect the gastrointestinal tract of mammals without activating a severe 
immune response by the host immune system. IgY also has 3-5 times higher affinity for 
antigens than mammalian IgG, reacts more rapidly with antigens when compared to IgG 
in competition assays, and does not react with rheumatoid factors—antibodies made by 
an organism against the Fc portion of its own antibodies and associated with autoimmune 
diseases (67). These characteristics make IgY an ideal candidate for various 
immunoassays and diagnostic tests. 
Safety 
As a normal component of the human diet, eggs are typically very safe to 
consume and IgY has been assigned “Generally Recognized As Safe” status by the FDA 
and the USDA (67). In various studies, even non-antigen specific IgY has been shown to 
have antimicrobial and immune enhancing effects (56). Although egg allergies are 
typically stimulated by proteins present in the egg white (e.g., albumins), they are a minor 
concern (67). However, some individuals are allergic to certain yolk components, thus, in 
areas where those allergies are prevalent, it is likely that more purified IgY would need to 
be used and the potential risks weighed against the potential benefits (56). Two other 
factors also indicate that egg allergies are less of a concern for anti-HRV IgY therapy: 
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first, that systemic tolerance to various egg proteins can be induced by oral administration 
of that protein, and second, that neonatal immune systems are often protected by breast-
feeding from developing allergies to oral antigens (56, 67, 70, 71). In one study, patients 
used IgY for up to 12 years with no adverse effects (72). Another safety concern is the 
development of resistant microorganisms. IgY, in comparison to antibiotic treatment, is 
far less likely to encourage development of resistant organisms since the antibody is 
usually produced against multiple epitopes of the whole organism rather than one 
component produced by one gene (67). 
Treatment of Human Disease 
 IgY shows great potential for the treatment and prevention of various diseases 
(particularly in the GI tract) and even neutralization of toxins from events such as snake 
bites and bacterial infections (57). IgY has been tested as a prophylaxis for dental caries 
in children, periodontitis, and oral candidiasis affecting immune compromised patients, 
showing potential for treating all of those oral infections (67, 73, 74). In the stomach, IgY 
has been used for various aspects of treatment and prevention of Helicobacter pylori 
colonization—significant because H. pylori colonization leads to gastric ulcers and even 
cancer and is becoming resistant to common antibiotics (58, 67, 75-77). IgY is also a 
candidate for treatment of Celiac disease and inflammatory bowel disease (57, 58). In 
addition to the GI tract diseases, acne-causing bacteria is a target for IgY therapy since 
IgY is easily incorporated into face-washes, creams, or cosmetic products (78). 
 One of the most informative studies regarding the viability and safety of IgY to 
treat human disease is a long-term study of patients with cystic fibrosis (CF).  Chronic 
Pseudomonas aeruginosa (PA) infections cause rapid decline in CF patients. For the 
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study of IgY treatment, participants used a daily mouthwash containing 50mg of anti-PA 
IgY in a 70mL quantity of mouthwash that each person gargled and swallowed every 
evening after brushing his or her teeth (72, 79, 80). Some patients were a part of the 
program for up to 12 years (as of 2008) and researchers found that IgY was just as 
effective as most antibiotic therapies to manage PA colonization. Further, no organisms 
developed resistance to IgY treatment, while it often only takes a single gene mutation 
for PA to exhibit resistance to many of the antibiotics used to treat CF patients. 
Additional damage occurs when broad-spectrum antibiotics are used, wiping out the 
normal flora of the patient and allowing other opportunistic infections to arise. At the end 
of the long-term study, patients in the IgY test group had statistically significant lower 
number of episodes of PA colonization combined with a lower probability of an early 
recurrence of chronic infection. Since the sample size was small, certain other differences 
between the IgY and control groups did not reach statistical significance, however the 
IgY group demonstrated healthier BMI, received fewer doses of antibiotics, and were not 
hospitalized for any lung infections during the treatment period (it was not clear if any of 
the control patients were hospitalized either). No adverse effects of the long-term IgY 
treatment were found over the entire study period—up to 12 years for some patients. 
 In addition to products for livestock and aquaculture industries, there are now IgY 
products available on the market for human consumption (57). These include anti-H. 
pylori urease IgY in yogurt and tablet form, a supplement containing IgY against 26 
common human enteric pathogens, and an IgY mix demonstrated to enhance athlete 
recovery time and performance. 
IgY in the Digestive Tract 
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Alone, IgY is active at a pH range of 3.5-11 and other substances such as sorbitol 
can stabilize IgY at lower pHs (67). In terms of its stability in the gastrointestinal tract, 
IgY is naturally resistant to digestion by trypsin and chymotrypsin but is more sensitive 
to pepsin when the enzyme is present at certain ratios and/or certain pH. However, at a 
pH of 5 or higher, IgY is also resistant to pepsin (67).  
There are a few methods that can be used to protect IgY from the harsh conditions 
of the stomach. These include administration of IgY in a sodium bicarbonate buffer, 
freeze-drying with gum-arabic, encapsulation of IgY in liposomes (e.g., egg 
lecithin/cholesterol liposomes) and encapsulation in chitosan-alginate (67). Chitosan-
alginate encapsulation of IgY has been demonstrated to protect the IgY from pepsin and 
acid in the stomach, while releasing it in the intestine to address enteric organisms (81-
83). This method of encapsulation allowed faster clearance of a bacterial infection with 
IgY in a pig model. Un-encapsulated IgY was more effective than typical antibiotic 
treatment, but compared to the encapsulated IgY the beneficial effects were delayed by 
three days. In a gnotobiotic piglet model of HRV infection, IgY was administered 
prophylactically in solution with bovine milk, and the therapy was still effective without 
further preparation/processing of IgY (56). 
Rotavirus Treatment Models 
 Various animal models of rotavirus infection along with clinical pediatric trials 
have shown that IgY is able to prevent and treat rotavirus gastroenteritis in a dose-
dependent manner. In 1998, Sarker and colleagues demonstrated that passive 
immunization with bovine serum antibodies could successfully treat rotavirus infection 
(84). As a follow-up, Sarker et al. performed a clinical trial in 2001 using an anti-HRV 
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IgY solution (yolk powder dissolved in water) to treat pediatric patients with the safer, 
more easily extracted avian immunoglobulin (55). While the IgY improved viral 
clearance, it did not reduce the duration or severity of the diarrhea. These investigators 
hypothesized that this was due to low dosage of IgY. In 2007, utilizing a mouse trial of 
rotavirus infection, the same researchers demonstrated that the efficacy of IgY was 
indeed dose dependent (85). Further, at higher doses, IgY treatment did reduce the 
duration of diarrhea in the mouse model. 
 In 2011, Buragohain and colleagues performed extensive in vitro and in vivo 
studies of IgY prophylaxis and therapy utilizing IgY from hens vaccinated against the 
five most prevalent serotypes of HRV (1,2,3,4, & 9) (53). For the in vitro neutralization 
studies, it was found that each anti-HRV IgY neutralized its own strain well. Anti-HRV-
3IgY was also able to neutralize all of the serotypes, while 1,2,4, & 9 were less effective 
on the other strains but still were able to neutralize more than one serotype. Since 
neutralization is a good indicator of the effectivity of an antiviral treatment in vivo, this 
indicated that IgY has promise as a therapeutic agent. As expected, the IgY from the 
unimmunized hens was not able to neutralize any of the rotavirus serotypes.  
 The in vivo experimentation performed by Buragohain and colleagues used a 
suckling mouse model of HRV infection. In this model, the post-inoculation IgY 
(therapeutic IgY) was effective in reducing diarrhea, viral load, and histopathological 
signs of infection in a dose dependent manner—the higher doses of IgY being more 
beneficial than the lower doses as shown by PCR and histological analysis. The mice that 
were fed IgY pre-inoculation with rotavirus (prophylactic IgY) were able to avoid many 
signs of infection at the times when infection is usually most physically visible. Viral 
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RNA in the intestinal lumen was undetectable and the histopathology of these mice was 
normal. These results indicate that avian IgY has promise as both a prophylaxis and 
treatment for human rotavirus infection in young children. 
 Around the same time, researchers in Argentina used a gnotobiotic (known-
microbiota) neonatal piglet model to mimic HRV infection and treatment in neonates 
(56). Chickens were immunized with two different antigenic substances: one group was 
immunized with VP6, and one group was immunized with the whole particles of a 
prevalent strain of human rotavirus, Wa G1P[8]. The so-called Wa HRV IgY was the 
most effective in neutralization assays as well as in the gnotobiotic piglet experiments. A 
crude extract of IgY was prepared via ammonium sulfate precipitation (see Appendix A) 
and mixed with bovine milk for administration to the piglets. At a high enough titer of 
IgY, the supplemented milk fully protected the piglets from HRV diarrhea and 
significantly lowered the amount of viral shedding in feces. At a lower titer, the IgY 
reduced the impact of HRV infection and delayed viral shedding but was unable to 
completely prevent it. Further, the effectiveness of the treatment was correlated with the 
presence of active anti-HRV IgY antibodies in the feces. This result indicates that at least 
some semi-purified IgY extract is able to survive the GI tract intact, and perhaps indicates 
that protection of IgY in the harsh gastric environment via encapsulation or other 
treatment may allow higher efficacy when smaller quantities of antigen specific IgY are 
administered. The anti-VP6 IgY did not perform well in neutralization assays in the 
laboratory, and it failed to prevent HRV gastroenteritis.  However, anti-VP6-IgY did 
demonstrate therapeutic benefits by lessening the severity of HRV gastroenteritis. This 
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may be partially due to other immune enhancing components of egg yolks which 
accompanied the crude IgY extract used in this experiment (56). 
In 2012, Rahman and colleagues published the results of another clinical trial in 
Myanmar where anti-HRV IgY was implemented as an adjunct therapy to standard 
supportive treatment of pediatric patients (54). They administered the IgY by mixing the 
freeze-dried yolk powder with maltitol and banana flavoring and administering four 
500mg doses of the mixture to each child in the IgY group daily. The four doses of the 
mixture contained a sum of about 30mg of antigen specific IgY (dosage clarified through 
personal correspondence, February 8, 2016). Rahman et al. found that the IgY treatment 
significantly reduced the duration of IV fluid administration, the amount of oral 
rehydration fluid intake, the duration of diarrhea and the average stool frequency. They 
also found that IgY treatment reduced the frequency of viral shedding (meaning that 
fewer rotavirus particles were spread into the environment). Patients who received the 
anti-HRV IgY treatment stopped needing IV treatment 3 days earlier than the control 
group, recovered 2 days faster from diarrhea and stopped shedding rotavirus 1 day earlier 
(54, 67). Overall, the variety of animal models of HRV infection that have been 
successfully treated with various antigen-specific IgY preparations combined with 
promising results from most recent clinical trials in Myanmar indicate that IgY is a viable 
treatment for human rotavirus in a developing country setting. 
IgY Addresses Current Gaps in Rotavirus Treatment 
 The low efficacy of current and emerging vaccines in developing countries, the 
inability to vaccinate immune compromised individuals (including the elderly) or 
children over 1 year of age who are out of the vaccine administration age range, the 
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difficulties of cultural barriers to ORS implementation, and difficulties of IV 
administration/availability all demonstrate the need for a better rotavirus treatment. It 
must be one that is effective, inexpensive, widely applicable and culturally acceptable. 
Further, it should complement local research ability and encourage economic growth of 
developing nations to provide local investment incentive.  
 Passive oral immunotherapy with IgY: (i) addresses cultural stigma by reducing 
diarrheal duration and severity which promotes its administration as a medicine and 
reduces the use of harmful antibiotics, (ii) reduces the duration of IV administration 
(allowing the more effective ORS to be used sooner), (iii) reduces the quantity of ORS 
needed for rehydration (facilitating caregiver follow-through with ORS for whole time 
period needed to rehydrate the child), (iv) is able to be used by all patients (immune 
compromised, malnourished, old or young, and those already infected with rotavirus) 
because it does not require the host immune system to prevent or clear the infection, (v) 
does not require a cold chain supply system and is easy to distribute, store and administer 
once manufactured, (vi) reduces viral shedding and thus the spread of infection, and has 
the potential (unlike vaccines) to prevent infection, thereby promoting an even greater 
public health benefit (22).  
Perhaps more importantly, IgY technology development offers an opportunity for 
the international community to partner with research that has already been performed in 
these developing countries, augmenting local research capabilities and interests. IgY 
could be mass produced in larger cities or developed on a small scale for local use in 
rural hospitals which have limited resources (e.g., less IV solutions and equipment for 
administration, reduced cold-storage capabilities).  IgY technology would be able to 
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evolve with each country’s needs as it developed both economically and socially. IgY 
technologies could be shifted to address other infections (e.g., H. pylori, acne, PA) 
without promoting antibiotic resistance, or it could be channeled to production of 
antibodies for diagnostic assays and other research applications. Nations are much more 
likely to invest their limited resources into developing an industry which they see as 
being able to benefit their nation economically in the long run as well as in the present. 
Therefore, anti-HRV IgY presents a unique solution that is medically, practically and 
economically promising and warrants serious consideration for investment by the 
international community as it seeks to address the global mortality of children under the 
age of 5. If action is taken soon, perhaps 20-sided creatures will be limited to children’s 
novels, bringing children’s imaginations to life instead of silencing them forever. 
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Appendix A 
Three Methods of IgY Precipitation 
Sequential Separation of Immunoglobulin Y 
Resulting extract of IgY exhibited a yield of 80.9%, was 98.7% pure, and retained 96.3% 
activity. 
1. Egg yolk was separated from egg white, diluted with 2 volumes of cold (4°C) 
distilled water (DW) and homogenized for 1 min using a hand blender (Kitchen 
Aid) at high speed (set at 9).  
2. After centrifugation at 3,400 × g for 30 min at 4°C, the supernatant was used to 
separate IgY and the precipitant for phosvitin separation.  
3. For IgY separation, the collected supernatant was diluted again with 3 volumes of 
cold (4°C) DW, kept in a cold room overnight to precipitate phospholipids and 
lipoproteins, and then centrifuged at 3,400 × g for 30 min at 4°C.  
4. The resulting supernatant was concentrated using ultrafiltration (membrane filter 
cut-off size: 50 kD, GE Healthcare Bio-Sciences Corp., Piscataway, NJ).  
5. Immunoglobulin Y in the concentrated solution was precipitated using 20% 
saturated ammonium sulfate (final concentration) and 15% NaCl (wt/ vol, final 
concentration) combination.  
6. The precipitant was collected after centrifugation at 3,400 × g for 30 min at 4°C, 
dissolved with 9 volumes of DW, and then precipitated again with the same 
(NH4)2SO4 + NaCl combination to improve purity.  
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7. The precipitant was dissolved with 9 volumes of DW, desalted using 
ultrafiltration, and then freeze-dried (FreeZone Freeze Dryer, Labconco Corp., 
Kansas City, MO). 
Source: (64) 
 
Rough Extraction of IgY Using Ammonium Sulfate Precipitation 
This precipitation method results in a rough extract of IgY, not a highly purified extract. 
1. Dilute egg yolks in distilled water (ratio 1:3). 
2. Centrifuge at 8,000g for 12 min at 4C to remove lipid. 
3. Incubate supernatant with 0.24 g/ml ammonium sulphate for 10 min at RT. 
4. Centrifuge at 10,000g for 12 min at 4C. 
5. Resuspend the pellet in 2M ammonium sulphate solution at the original egg yolk 
volume and incubate at RT for 10 min. 
6. Centrifuge the solution at 10,000g for 12 min at 4C. 
7. Resuspend pellet in PBS (pH 7.4) at a 1:10 ratio of the original volume of the egg 
yolk (not the diluted solution). 
8. Dialyze against PBS, sterilize by filtration (0.22um pore size membrane filter) 
and store at -20C until used. 
Source: (56)  
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Extraction of IgY Using Polyethylene Glycol Precipitation 
1. The eggshell is carefully cracked and the yolk is transferred to a "yolk spoon" in 
order to remove as much egg white as possible. 
2. The yolk is transferred to a filter paper and rolled to remove remaining egg white, 
then the yolk skin is cut with a lancet or a similar instrument (pipette tip). The 
yolk is poured into a 50 ml tube and the egg volume is registered (V1). 
3. Twice the egg yolk volume of PBS is mixed with the yolk (ΣV1+V2), thereafter 
3.5 % PEG 6000 (in gram, pulverized) of the total volume is added and vortexed, 
followed by 10 min rolling on a rolling mixer. That step of the extraction 
procedure separates the suspension in two phases. One phase consists of "yolk 
solids and fatty substances" and a watery phase containing IgY and other proteins. 
4. The tubes are centrifuged at 4°C for 20 min (10,000 rpm according to 13,000 x g, 
Heraeus Multifuge 3SR+, fixed angle rotor). The supernatant (V3) is poured 
through a folded filter and transferred to a new tube. 
5. 8.5 % PEG 6000 in gram (calculated according to the new volume) are added to 
the tube, vortexed and rolled on a rolling mixer as in step 3. 
6. Repeat step 4 with the difference that the supernatant is discarded. 
7. The pellet is carefully dissolved in 1 ml PBS by means of a glass stick and the 
vortexer. PBS is added to a final volume of 10 ml (V4). The solution is mixed 
with 12 % PEG 6000 (w/v, 1.2 gram) and treated as in step 3 (vortex, rolling 
mixer). 
9. Repeat step 6 and dissolve the pellet carefully in 800 μl PBS (glass stick and 
vortex). Wait for the air bubbles to disappear and then transfer (pipette) the 
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extract to a dialysis capsule. Rinse the tube with 400 μl PBS and add the volume 
to the dialysis device (V5). 
10. The extract is dialyzed over night in 0.1 % saline (1,600 ml) and gently stirred by 
means of a magnetic stirrer. The next morning, the saline is replaced by PBS and 
dialyzed for another three hours. 
11. Thereafter the IgY-extract is pulled from the dialysis capsule by a pipette and 
transferred to 2ml tubes. The final volume is around 2 ml (V6). 
12. The protein content (mg/mL) of the samples is measured photometrically at 280 
nm (1:50 diluted with PBS) and calculated according to the Lambert-Beer law 
with an extinction coefficient of 1.33 for IgY (purity and recovery are around 
80%). 
13. It is advisable to store the samples in aliquots at -20°C (do not freeze the samples 
at -70°C). 
Source: (62) 
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Appendix B 
Figure Copyright Permissions 
Figure 1 Permissions 
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Figure 2 Permissions 
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Figure 3 and Figure 4 Permissions 
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Figure 5 Permissions 
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Figure 6 Permissions 
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